Champions Oncology Inc
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Champions Oncology's stock, believing it will increase from its current price.
Financial Health
Champions Oncology is performing well with solid revenues and cash flow, indicating strong operational health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CSBR
Humble & Hungry
Get exclusive access to ambitious challenger companies positioned to outperform their larger competitors. Our professional analysts have carefully selected these nimble innovators for their potential to deliver explosive growth by disrupting established industry giants.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Tumour Avatars Insight
Patient‑derived tumour models can help predict drug responses and support biomarker discovery, though scientific validation and commercial uptake are ongoing.
Partnerships Drive Revenue
Contracts and collaborations with pharma firms are central to growth, but revenues may be irregular and depend on successful client programmes.
Small‑Cap Considerations
With a roughly $92M market cap, expect higher volatility and lower liquidity than larger peers; investors should weigh this alongside potential upside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
